Product Information
ALREX 0.2% EYE DROPS is a brand product labeled by Bausch & Lomb Incorporated, priced at $58.0100 per ML under NDC 24208035310. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Mar 9, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the loteprednol etabonate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2 mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208035310
Classification
Brand
Dosage Form
SUSPENSION/ DROPS
Route
OPHTHALMIC
Effective Date
7/22/2026
Active Ingredients
LOTEPREDNOL ETABONATEApproval Type
New Drug (NDA)
FDA Application
NDA020803FDA Approved
3/9/1998
TE Code
AB
On Market Since
3/9/1998
Pharmacological Classes
Price Statistics
The NADAC for ALREX 0.2% EYE DROPS has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 111.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $58.0100 per ML |
|---|---|
| All-time high | $58.2584 (May 14, 2025) |
| All-time low | $27.3930 (Nov 28, 2013) |
| 52-week high | $58.0517 |
| 52-week low | $57.8963 |
| Median price | $45.6497 |
| Average price | $45.2033 |
| Largest weekly change | +10.0% (Jan 14, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 47% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
loteprednol etabonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALREX 0.2% EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for ALREX 0.2% EYE DROPS, manufactured by Bausch & Lomb Incorporated, is $58.0100 per ML (NDC 24208035310), effective Sep 30, 2026.
How has the price of ALREX 0.2% EYE DROPS changed over time?
Over the history we have for it, the NADAC for ALREX 0.2% EYE DROPS has risen 111.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ALREX 0.2% EYE DROPS?
Since Nov 28, 2013, the NADAC for ALREX 0.2% EYE DROPS has ranged from a low of $27.3930 (Nov 28, 2013) to a high of $58.2584 (May 14, 2025), with a median of $45.6497 per ML.
Are there cheaper alternatives to ALREX 0.2% EYE DROPS?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LOTEPREDNOL ETABONATE 0.2% DRP, is $30.7171 per ML — about 47% below ALREX 0.2% EYE DROPS.
Who manufactures ALREX 0.2% EYE DROPS?
ALREX 0.2% EYE DROPS (NDC 24208035310) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.